Stay updated on Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.

Latest updates to the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference12%

- Check26 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.3%

- Check40 days agoChange DetectedNow shows Revision: v3.0.2, replacing v3.0.1, and the Back to Top element has been removed. These are cosmetic changes with no impact on core content or critical information.SummaryDifference0.7%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%

- Check54 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information.SummaryDifference16%

- Check69 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%

Stay in the know with updates to Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.